Andrew Kuykendall, MD

Andrew Kuykendall, MD, assistant member at the Moffitt Cancer Center, discusses the current treatment landscape for the patients with myelofibrosis (MF) and how this evolved over the last decade.

For a long time, Kuykendall says the only FDA-approved therapy for the treatment of patients with MF was ruxolitinib (Jakafi). Physicians relied on this therapy for almost a decade to treat disease-related symptoms and symptoms related to the spleen.

However, in August 2019, the FDA granted approval to fedratinib (Inrebic). Fedratinib is now available as treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post-polycythemia vera or post-essential thrombocythemia MF. Kuykendall says physicians have been waiting a long time for a new therapy to become approved in the setting of patients with MF.

<< For more on the FDA approval of fedratinib in myelofibrosis

Videos

Andrew Kuykendall, MD, discusses the current treatment landscape for the patients with myelofibrosis and how this evolved over the last decade.

Exploring FDA-Approved Treatment Options for Patients With Myelofibrosis

Andrew Kuykendall, MD, assistant member at the Moffitt Cancer Center, discusses the background to the JAK2 inhibitor fedratinib (Inrebic), which was

approved by the FDA in August 2019 for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis

(MF), including postpolycythemia vera or post&ndash;essential thrombocythemia MF.

Kuykendall says fedratinib has an interesting story. It&rsquo;s a relatively old drug that had previously been through extensive clinical trials years ago and has now re-emerged. He calls this a rising-from-the-ashes story to describe the evolution of fedratinib and its move toward the treatment landscape for patients with MF.

Andrew Kuykendall, MD, discusses the background to the JAK2 inhibitor fedratinib (Inrebic), which was&nbsp;approved by the FDA in August 2019 for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post&ndash;polycythemia vera or post&ndash;essential thrombocythemia MF.

Andrew Kuykendall, MD | Authors

Articles

Exploring FDA-Approved Treatment Options for Patients With Myelofibrosis

Fedratinib Re-emerges as FDA-Approved Treatment of Myelofibrosis